One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the ...

CHICAGO (Reuters) - Diabetics with stable heart disease do just as well taking drugs alone as getting quick angioplasty or bypass surgery to open blocked heart arteries, U.S. researchers said on ...

Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study, which includes ...

Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study, which includes ...

Patients with diabetes mellitus and coronary artery disease (CAD) have been shown to have better outcomes with drug-eluting stents (DES) compared with bare-metal stents (BMS). This trial was aimed at ...

PARIS — For the first time, there is compelling evidence that the degree of poor glycemic control in patients with type 2 diabetes is a relative risk factor for stent failure after a percutaneous ...

Patients with diabetes have an increased risk of complications after stent implantation, according to a study from Karolinska Institutet in Sweden published in Diabetes Care. The study, which includes ...

Please provide your email address to receive an email when new articles are posted on . Among patients with diabetes, those taking a GLP-1 had better 3-year survival rates after PCI for a heart attack ...

Two P2Y12 inhibitors often used interchangeably, ticagrelor and prasugrel (antiplatelet medications prescribed to prevent the formation of blood clots), had different impacts on outcomes in patients ...